Treatment with ICB has improved clinical outcomes across numerous cancers, most notably metastatic melanoma (MM) where treatment with combination ICB to CTLA-4 (ipilimumab) and PD-1 (nivolumab) for MM is associated with extending median survival from months to beyond 5 years (4, 5). This evidence concerns the gene CTLA4 and Miyoshi myopathy.